1Cotzias G, Papavaslllou P, Gellene R.Modification of parkinsonlsm -chronic treatment with L-dopa. N Engl J Med. 1969;280:337-345.
2Comella C. Tanner C. The Side Effects of Chronic Treatment in Parkinson's Disease. Blackwell Science: Malden, Mass; 1999:209-216.
3Fahn S. Is levodopa toxic? Neurology. 1996;47(suppl 3):S184-S195.
4Shulman L Levodopa toxicity in Parkinson disease: reality of myth? reality-practice patterns should change. Arch Neurol 2000;57:406-407.
5Lees A, Stem G. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neutosurg Psychiatry. 1981;44:1020-1023
6Adler C, Sethi K, Hauser R, et al. Roplnirole for the treatment of early Parkinson's disease. Neurology. 1997;49:393 -399.
7Parkinson Study Group. Safety and efficacy of pramipexole in early parkinson disease: a randomized dose-ranging study. JAMA. 1997;27B:125-130.
8Shannon K. Bennett J, Friedmann J, for the PSG. Efficacy of Pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology. 1997;49:724-728.
9Parkinson Study Group. Pramipaxole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA. 2000;284:1931-1938.
10Rascol O, Brooks D, Korczyn A, et al, for the 056 Study Group. A five-year study of th e incidence of dyskinesia, In patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484-1491.
